New drug targets Cancer's genetic weakness
NCT ID NCT04439175
Summary
This study is testing an experimental drug called taselisib for people with advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug aims to block a protein that helps cancer cells grow, with the goal of shrinking tumors or stopping their growth. It is for patients with various advanced or hard-to-treat cancers (like lymphoma or solid tumors) who have this mutation but not certain other genetic changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.